Cosmos Health (NASDAQ:COSM – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.11), FiscalAI reports. The business had revenue of $18.99 million for the quarter, compared to analyst estimates of $19.42 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%.
Cosmos Health Stock Performance
Shares of COSM stock opened at $0.21 on Wednesday. The firm has a 50-day moving average of $0.22 and a 200-day moving average of $0.30. The company has a market cap of $12.40 million, a P/E ratio of -0.32 and a beta of 4.80. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.08 and a quick ratio of 0.92. Cosmos Health has a one year low of $0.16 and a one year high of $1.32.
Insider Activity
In other news, CEO Grigorios Siokas acquired 766,284 shares of Cosmos Health stock in a transaction on Wednesday, July 29th. The stock was acquired at an average cost of $0.18 per share, with a total value of $137,931.12. Following the transaction, the chief executive officer owned 14,248,092 shares of the company’s stock, valued at approximately $2,564,656.56. This trade represents a 5.68% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Georgios Terzis acquired 168,135 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was purchased at an average price of $0.25 per share, with a total value of $42,033.75. Following the purchase, the chief financial officer owned 2,235,398 shares in the company, valued at approximately $558,849.50. The trade was a 8.13% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 2,204,138 shares of company stock worth $457,137. 26.15% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cosmos Health has an average rating of “Sell”.
Read Our Latest Stock Report on COSM
Cosmos Health Company Profile
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Featured Stories
- Five stocks we like better than Cosmos Health
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
